Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome

被引:101
作者
Hulstein, J. J. J.
Heimel, P. J. . Van Runnard
Franx, A.
Lenting, P. J.
Bruinse, H. W.
Silence, K.
De Groot, Ph. G.
Fijnheer, R.
机构
[1] Univ Med Ctr Utrecht, Dept Haematol, NL-3584 CX Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Perinatol & Gynaecol, NL-3584 CX Utrecht, Netherlands
[3] St Elizabeth Hosp, Dept Obstet & Gynaecol, Tilburg, Netherlands
[4] Ablynx, Ghent, Belgium
[5] Jeroen Bosch Hosp, Dept Internal Med, Den Bosch, Netherlands
关键词
active VWF; HELLP syndrome; thrombotic microangiopathy;
D O I
10.1111/j.1538-7836.2006.02205.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome is a severe complication of pre-eclampsia in pregnancy, characterized by microvascular platelet thrombi. Activation of the endothelium is thought to play a key role in pre-eclampsia and HELLP syndrome. Activation of endothelial cells may lead to release of von Willebrand factor (VWF) multimers, which are highly reactive with platelets. Normally, newly released multimers are cleaved by ADAMTS13, resulting in less reactive derivatives. Objective: We hypothesized that HELLP syndrome is characterized by increased amounts of active VWF compared with healthy pregnancy and pre-eclampsia, due to acute activation of endothelial cells. This might contribute to thrombocytopenia and thrombotic microangiopathy. Methods: Active VWF and ADAMTS13 activity were measured in healthy pregnant volunteers (n=9), patients with pre-eclampsia (n=6) and patients with HELLP syndrome (n=14) at similar gestational ages. To study the role of endothelial cell activation, the propeptide/mature VWF ratio was determined, and VWF released by cultured endothelial cells was analyzed. Results: Active VWF levels were increased 2.1-fold in HELLP syndrome compared with healthy pregnant volunteers (P < 0.001) and 1.6-fold compared with patients with pre-eclampsia (P=0.001). ADAMTS13 activity was moderately decreased in patients with HELLP syndrome compared with healthy pregnant volunteers (P < 0.004), but not compared with patients with pre-eclampsia. The propeptide/mature VWF ratio was increased 1.7-fold compared with healthy pregnant volunteers (P < 0.001) and 1.5-fold compared with patients with pre-eclampsia (P < 0.05). A significant correlation was found between this ratio and the activation factor of VWF (r=0.68, P < 0.001). The amount of active VWF was increased 1.4-fold in medium of stimulated endothelial cells when compared with non-stimulated cells (P < 0.05). Conclusion: Acute endothelial cell activation in HELLP syndrome and decreased ADAMTS13 activity result in increased amounts of active VWF. This might explain the consumptive thrombocytopenia and thrombotic microangiopathy associated with HELLP syndrome. Inhibition of circulating active VWF could be a potential new approach in the treatment of patients with HELLP syndrome.
引用
收藏
页码:2569 / 2575
页数:7
相关论文
共 20 条
[1]
Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex:: studies using optical tweezers [J].
Arya, M ;
Anvari, B ;
Romo, GM ;
Cruz, MA ;
Dong, JF ;
McIntire, LV ;
Moake, JL ;
López, JA .
BLOOD, 2002, 99 (11) :3971-3977
[2]
Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans [J].
Borchiellini, A ;
Fijnvandraat, K ;
tenCate, JW ;
Pajkrt, D ;
vanDeventer, SJH ;
Pasterkamp, G ;
MeijerHuizinga, F ;
ZwartHuinink, L ;
Voorberg, J ;
vanMourik, JA .
BLOOD, 1996, 88 (08) :2951-2958
[3]
Coppola R, 2003, HAEMATOLOGICA, V88, P39
[4]
BIOCHEMICAL CORROBORATION OF ENDOTHELIAL INVOLVEMENT IN SEVERE PREECLAMPSIA [J].
FRIEDMAN, SA ;
SCHIFF, E ;
EMEIS, JJ ;
DEKKER, GA ;
SIBAI, BM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 172 (01) :202-203
[5]
GILL JC, 1987, BLOOD, V69, P1691
[6]
Structures of glycoprotein Ibα and its complex with von Willebrand factor A1 domain [J].
Huizinga, EG ;
Tsuji, S ;
Romijn, RAP ;
Schiphorst, ME ;
de Groot, PG ;
Sixma, JJ ;
Gros, P .
SCIENCE, 2002, 297 (5584) :1176-1179
[7]
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS 13 deficiency and von Willebrand disease type 2B [J].
Hulstein, JJJ ;
de Groot, PG ;
Silence, K ;
Veyradier, A ;
Fijnheer, R ;
Lenting, PJ .
BLOOD, 2005, 106 (09) :3035-3042
[8]
CULTURE OF HUMAN ENDOTHELIAL CELLS DERIVED FROM UMBILICAL VEINS - IDENTIFICATION BY MORPHOLOGIC AND IMMUNOLOGICAL CRITERIA [J].
JAFFE, EA ;
NACHMAN, RL ;
BECKER, CG ;
MINICK, CR .
JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (11) :2745-2756
[9]
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay [J].
Kokame, K ;
Nobe, Y ;
Kokubo, Y ;
Okayama, A ;
Miyata, T .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (01) :93-100
[10]
Thrombomodulin, von Willebrand factor and E-selectin as plasma markers of endothelial damage/dysfunction and activation in pregnancy induced hypertension [J].
Nadar, SK ;
Al Yemeni, E ;
Blann, AD ;
Lip, GYH .
THROMBOSIS RESEARCH, 2004, 113 (02) :123-128